Literature DB >> 25589651

Immune screening identifies novel T cell targets encoded by antisense reading frames of HIV-1.

Christoph T Berger1, Anuska Llano2, Jonathan M Carlson3, Zabrina L Brumme4, Mark A Brockman4, Samandhy Cedeño2, P Richard Harrigan5, Daniel E Kaufmann6, David Heckerman3, Andreas Meyerhans7, Christian Brander8.   

Abstract

Cytotoxic-T lymphocyte (CTL) responses to epitopes in alternative HIV reading frames have been reported. However, the extent of CTL responses to putative proteins encoded in antisense reading frames is unknown. Using sequence alignments and computational approaches, we here predict five potential antisense HIV proteins and characterize common CTL responses against them. Results suggest that antisense-derived sequences are commonly transcribed and translated and could encode functional proteins that contain important targets of anti-HIV cellular immunity.
Copyright © 2015, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 25589651      PMCID： PMC4403399          DOI： 10.1128/JVI.03435-14

Source DB:  PubMed          Journal:  J Virol        ISSN： 0022-538X            Impact factor:   5.103


  18 in total

1.  Poorly soluble peptides can mimic authentic ELISPOT responses.

Authors:  R Karl Karlsson; Wim Jennes; Kimberly Page-Shafer; Douglas F Nixon; Barbara L Shacklett
Journal:  J Immunol Methods       Date:  2004-02-01       Impact factor: 2.303

2.  High-functional-avidity cytotoxic T lymphocyte responses to HLA-B-restricted Gag-derived epitopes associated with relative HIV control.

Authors:  Christoph T Berger; Nicole Frahm; David A Price; Beatriz Mothe; Musie Ghebremichael; Kari L Hartman; Leah M Henry; Jason M Brenchley; Laura E Ruff; Vanessa Venturi; Florencia Pereyra; John Sidney; Alessandro Sette; Daniel C Douek; Bruce D Walker; Daniel E Kaufmann; Christian Brander
Journal:  J Virol       Date:  2011-07-13       Impact factor: 5.103

3.  Human immunodeficiency virus may encode a novel protein on the genomic DNA plus strand.

Authors:  R H Miller
Journal:  Science       Date:  1988-03-18       Impact factor: 47.728

4.  Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome.

Authors:  R A Koup; J T Safrit; Y Cao; C A Andrews; G McLeod; W Borkowsky; C Farthing; D D Ho
Journal:  J Virol       Date:  1994-07       Impact factor: 5.103

Review 5.  In search of antisense.

Authors:  Giovanni Lavorgna; Dvir Dahary; Ben Lehner; Rotem Sorek; Christopher M Sanderson; Giorgio Casari
Journal:  Trends Biochem Sci       Date:  2004-02       Impact factor: 13.807

6.  Human immunodeficiency virus type 1-specific CD8+ T-cell responses during primary infection are major determinants of the viral set point and loss of CD4+ T cells.

Authors:  Hendrik Streeck; Jonathan S Jolin; Ying Qi; Bader Yassine-Diab; Randall C Johnson; Douglas S Kwon; Marylyn M Addo; Chanson Brumme; Jean-Pierre Routy; Susan Little; Heiko K Jessen; Anthony D Kelleher; Frederick M Hecht; Rafick-Pierre Sekaly; Eric S Rosenberg; Bruce D Walker; Mary Carrington; Marcus Altfeld
Journal:  J Virol       Date:  2009-05-20       Impact factor: 5.103

7.  Consistent cytotoxic-T-lymphocyte targeting of immunodominant regions in human immunodeficiency virus across multiple ethnicities.

Authors:  Nicole Frahm; B T Korber; C M Adams; J J Szinger; R Draenert; M M Addo; M E Feeney; K Yusim; K Sango; N V Brown; D SenGupta; A Piechocka-Trocha; T Simonis; F M Marincola; A G Wurcel; D R Stone; C J Russell; P Adolf; D Cohen; T Roach; A StJohn; A Khatri; K Davis; J Mullins; P J R Goulder; B D Walker; C Brander
Journal:  J Virol       Date:  2004-03       Impact factor: 5.103

8.  Influence of HAART on alternative reading frame immune responses over the course of HIV-1 infection.

Authors:  Stephane Champiat; Rui André Saraiva Raposo; Nicholas J Maness; John L Lehman; Sean E Purtell; Aaron M Hasenkrug; Jacob C Miller; Hansi Dean; Wayne C Koff; Marisa Ailin Hong; Jeffrey N Martin; Steven G Deeks; Gerald E Spotts; Christopher D Pilcher; Fredrick M Hecht; Esper G Kallas; Keith E Garrison; Douglas F Nixon
Journal:  PLoS One       Date:  2012-06-29       Impact factor: 3.240

9.  Viral adaptation to immune selection pressure by HLA class I-restricted CTL responses targeting epitopes in HIV frameshift sequences.

Authors:  Christoph T Berger; Jonathan M Carlson; Chanson J Brumme; Kari L Hartman; Zabrina L Brumme; Leah M Henry; Pamela C Rosato; Alicja Piechocka-Trocha; Mark A Brockman; P Richard Harrigan; David Heckerman; Daniel E Kaufmann; Christian Brander
Journal:  J Exp Med       Date:  2010-01-11       Impact factor: 14.307

10.  CD8 T cell response and evolutionary pressure to HIV-1 cryptic epitopes derived from antisense transcription.

Authors:  Anju Bansal; Jonathan Carlson; Jiyu Yan; Olusimidele T Akinsiku; Malinda Schaefer; Steffanie Sabbaj; Anne Bet; David N Levy; Sonya Heath; Jianming Tang; Richard A Kaslow; Bruce D Walker; Thumbi Ndung'u; Philip J Goulder; David Heckerman; Eric Hunter; Paul A Goepfert
Journal:  J Exp Med       Date:  2010-01-11       Impact factor: 14.307
View more
  13 in total

1.  HIV-1 Antisense Protein of Different Clades Induces Autophagy and Associates with the Autophagy Factor p62.

Authors:  Zhenlong Liu; Cynthia Torresilla; Yong Xiao; Phuong Trang Nguyen; Clément Caté; Karina Barbosa; Éric Rassart; Shan Cen; Steve Bourgault; Benoit Barbeau
Journal:  J Virol       Date:  2019-01-04       Impact factor: 5.103

2.  HLA-I Associated Adaptation Dampens CD8 T-Cell Responses in HIV Ad5-Vectored Vaccine Recipients.

Authors:  Sushma Boppana; Sarah Sterrett; Jacob Files; Kai Qin; Andrew Fiore-Gartland; Kristen W Cohen; Stephen C De Rosa; Anju Bansal; Paul A Goepfert
Journal:  J Infect Dis       Date:  2019-10-08       Impact factor: 5.226

3.  The HIV-1 Antisense Protein ASP Is a Transmembrane Protein of the Cell Surface and an Integral Protein of the Viral Envelope.

Authors:  Yvonne Affram; Juan C Zapata; Zahra Gholizadeh; William D Tolbert; Wei Zhou; Maria D Iglesias-Ussel; Marzena Pazgier; Krishanu Ray; Olga S Latinovic; Fabio Romerio
Journal:  J Virol       Date:  2019-10-15       Impact factor: 5.103

Review 4.  Defective HIV-1 genomes and their potential impact on HIV pathogenesis.

Authors:  Jeffrey Kuniholm; Carolyn Coote; Andrew J Henderson
Journal:  Retrovirology       Date:  2022-06-28       Impact factor: 3.768

5.  Concomitant emergence of the antisense protein gene of HIV-1 and of the pandemic.

Authors:  Elodie Cassan; Anne-Muriel Arigon-Chifolleau; Jean-Michel Mesnard; Antoine Gross; Olivier Gascuel
Journal:  Proc Natl Acad Sci U S A       Date:  2016-09-28       Impact factor: 11.205

Review 6.  Antigen processing and presentation in HIV infection.

Authors:  Julie Boucau; Sylvie Le Gall
Journal:  Mol Immunol       Date:  2018-04-07       Impact factor: 4.407

7.  Human retroviral antisense mRNAs are retained in the nuclei of infected cells for viral persistence.

Authors:  Guangyong Ma; Jun-Ichirou Yasunaga; Kazuya Shimura; Keiko Takemoto; Miho Watanabe; Masayuki Amano; Hirotomo Nakata; Benquan Liu; Xiaorui Zuo; Masao Matsuoka
Journal:  Proc Natl Acad Sci U S A       Date:  2021-04-27       Impact factor: 11.205

Review 8.  HIV-1 Natural Antisense Transcription and Its Role in Viral Persistence.

Authors:  Rui Li; Rachel Sklutuis; Jennifer L Groebner; Fabio Romerio
Journal:  Viruses       Date:  2021-04-29       Impact factor: 5.048

Review 9.  Implication of Different HIV-1 Genes in the Modulation of Autophagy.

Authors:  Zhenlong Liu; Yong Xiao; Cynthia Torresilla; Éric Rassart; Benoit Barbeau
Journal:  Viruses       Date:  2017-12-18       Impact factor: 5.048

10.  HIV LTR-Driven Antisense RNA by Itself Has Regulatory Function and May Curtail Virus Reactivation From Latency.

Authors:  Mie Kobayashi-Ishihara; Kazutaka Terahara; Javier P Martinez; Makoto Yamagishi; Ryutaro Iwabuchi; Christian Brander; Manabu Ato; Toshiki Watanabe; Andreas Meyerhans; Yasuko Tsunetsugu-Yokota
Journal:  Front Microbiol       Date:  2018-05-25       Impact factor: 5.640
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.